Report on the risk assessment of 4,4′-DMAR in the framework of the Council Decision on new psychoactive substances


This publication presents the data and findings of the risk assessment on 4,4’-DMAR (4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014. The main part of the publication, the Risk Assessment Report, examines the health and social risks of the drug, information on international trafficking and the involvement of organised crime, and the potential implications of subjecting the drug to control measures. On the basis of this report the Council decided on 8 October 2015 that 4,4’-DMAR should be subject to control measures across the Member States.

Download as PDF

Table of contents

  • Foreword
  • EMCDDA actions on monitoring and responding to new drugs
  • EMCDDA–Europol Joint Report on 4,4'-DMAR: a summary
  • Risk Assessment Report of a new psychoactive substance: 4,4'-DMAR
  • Annex 1: Technical report on 4,4'-DMAR
  • Council Decision on subjecting 4,4'-DMAR to control measures
  • Abbreviations
  • Participants of the risk assessment meeting